Company profile: Freeline Therapeutics
1.1 - Company Overview
Company description
- Provider of transformative adeno-associated virus-vector-mediated systemic gene therapies for systemic debilitating diseases, using a designed AAV vector and capsid with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Freeline Therapeutics
Spindiag
HQ: Germany
Website
- Description: Provider of an easy-to-use, compact, automated point-of-care PCR system for broad, fast, and affordable pathogen detection. The Rhonda player with Rhonda disks detects infectious agents—including SARS-CoV-2, Influenza A/B, RSV, and MRSA—with results in under one hour; the SARS-CoV-2 disk supports direct swab insertion. The Rhonda app displays results for mobile use, and test outcomes can be transferred directly into patient records.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spindiag company profile →
Nightingale Health
HQ: Finland
Website
- Description: Provider of pioneering blood-testing services and proprietary blood analysis technology that delivers deep health insights, identifies disease risks from a single sample, and measures the effects of lifestyle interventions. Offers Nightingale Pro data platform for detecting population-level disease risks and preventative health needs, and biomarker analysis services for researchers across blood, urine, and dried blood spot samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nightingale Health company profile →
Tepnel Pharma Services
HQ: United Kingdom
Website
- Description: Provider of independent contract research services supporting the drug development pipeline at the Rx/Dx interface, delivering quality control laboratory analysis to help advance precision medicine and a value healthcare system that improves patient outcomes; part of a leading global healthcare and diagnostics company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tepnel Pharma Services company profile →
GenEdit
HQ: United States
Website
- Description: Provider of a proprietary non-viral, non-lipid polymer nanoparticle platform (NanoGalaxy) for safe, efficient delivery of genetic medicine payloads—including nucleic acids, therapeutic proteins, and CRISPR/Cas9—to specific tissues. Offers tissue selectivity, payload flexibility, ability to redose without immune response, and scalable manufacturing with batch-to-batch purity and long-term stability that reduces cold-chain logistics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenEdit company profile →
CustomArray
HQ: United States
Website
- Description: Provider of oligonucleotide pool libraries to many of the world’s premier academic and industrial organizations for applications including synthetic biology, gene synthesis, CRISPR, targeted sequencing, complex DNA libraries, shRNA libraries, and DNA data storage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CustomArray company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Freeline Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Freeline Therapeutics
2.2 - Growth funds investing in similar companies to Freeline Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Freeline Therapeutics
4.2 - Public trading comparable groups for Freeline Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →